Fort Wayne, Indiana — Fort Wayne Medical Oncology and Hematology (FWMOH) is pleased to announce its newly formed partnership with nationally acclaimed Translational Research in Oncology-US (TRIO-US). Known for its proven track record in bringing translational research into clinical trial settings, TRIO-US offers FWMOH new opportunities to participate in a wide range of clinical trials on a national scale.
FWMOH has a long and successful history of participating in clinical trials and is the first and only oncology practice in the region to be invited into research partnership with TRIO-US.
“We are thrilled to join the network of researchers through TRIO-US,” says Dr. Sunil Babu, director of research at FWMOH. “This partnership will create much greater access to a large portfolio of clinical trials, giving our patients a chance to receive what is often cutting-edge treatment without the added stress of traveling to a large, metropolitan area.”
In order to join the TRIO-US network, cancer centers must participate in a months-long vetting process. According to Allison Muff, site liaison outreach coordinator with TRIO-US, FWMOH was an attractive research partner in part because of its long history of participating in clinical trials, as well as its two different sites within the same practice, bringing more principal investigators to the table and allowing TRIO-US to reach a wider range of patients. “In turn,” she says, “we offer FWMOH patients greater access to more trials and treatment options.”
As an added bonus, FWMOH will participate in a national research conference hosted by TRIO-US on the campus of UCLA, where national researchers discuss the latest findings in cancer research.
About FWMOH: Fort Wayne Medical Oncology and Hematology provides state-of-the-art cancer and hematological (blood disorders) treatment through its team of dedicated physicians and health-care professionals. Since 1977, Fort Wayne Medical Oncology and Hematology has treated thousands of cancer patients in more than 40 areas of cancer, as well as patients with blood disorders. FWMOH is the only medical oncology group in northeast Indiana to obtain the highly acclaimed QOPI certification in 2014 and the Excellence in Clinical Research award during the annual meeting at American Society of Clinical Oncology in 2008.
About TRIO-US: TRIO-US is a not-for-profit clinical research organization dedicated to advancing translational cancer research by bringing forward innovative and targeted therapeutic concepts into the clinical trial setting. TRIO-US has a proven track record of delivering clinical trial results accurately, efficiently, and on time.